Senseonics Holdings, Inc. (NASAQ: SENS) is a medical technology company working on revolutionizing the world of continuous glucose monitoring (CGM) systems. Based in Germantown, Maryland, USA, Senseonics Holdings was incorporated in 2014 and primarily serves the diabetes community.
The company specializes in the design, development, and commercialization of glucose monitoring products intended to help individuals with diabetes monitor their blood glucose levels in a more manageable, convenient, and efficient manner. With a mission to enhance the quality of life of people with diabetes, Senseonics leverages science, technology, and innovation to create products that make glucose monitoring simpler, providing results with accuracy and reliability.
Their first product, Eversense® CGM system, has attracted considerable attention. Eversense comprises a sensor, typically placed under the skin, which provides glucose calculations for up to 90 days. It has been approved by the FDA for use in the USA, as well as gaining CE Mark approval in Europe. More recently, Senseonics has advanced its CGM system, introducing Eversense® XL, offering extended longevity with an insertion duration of up to 180 days.
Senseonics' incredible developments are not without recognition. The uniqueness of their CGM system has carved a distinctive niche for them in the competitive medical technology market. They maintain a strong commitment to operational efficiency, product innovation, and quality of products, values that have enabled them to establish solid relationships with their customers, shareholders, and the wider diabetes community.
The market potential for CGM systems is significant, as they offer a more sophisticated and effective way to manage diabetes, a condition affecting millions of people worldwide. As a result, Senseonics has become an appealing prospect for many investors. Despite the challenges associated with stringent regulatory requirements and competitive pressure, the company has maintained steady progress, demonstrating the robustness of its technology and its potential for growth in the industry.
Senseonics has shown commitment and resilience, forging partnerships with medical associations, healthcare professionals, and diabetes educators to fuel its innovative strategy and growth journey. As a company, they always ensure they uphold the highest levels of integrity, safety, and excellence, a statement that resonates in their commitment to revolutionize diabetes management.
In conclusion, Senseonics Holdings, Inc. stands as a beacon of innovation in medical technology, specifically in diabetes care. It is a company known to turn difficulties into opportunities, foucsing on life-changing inventions that offer a new lease of life for millions of diabetes patients globally. Its relentless commitment to enhancing diabetes management through novel technologies sets it head and shoulders above the competition, with future prospects that are incredibly promising.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Senseonics Holdings, Inc. has initiated its first-in-human clinical feasibility study for Freedom, an investigational continuous glucose monitoring (CGM) system. This new system aims to eliminate the need for an on-body transmitter by integrating a battery and Bluetooth Low Energy (BLE) transceiver directly into a fully implantable sensor, offering invisible CGM for up to a year. The study will assess the device's safety and performance, with pivotal trials planned for 2027 and a commercial launch targeted for 2028.
Senseonics Holdings (NASDAQ:SENS) has initiated its first human clinical study for Freedom, an investigational continuous glucose monitoring (CGM) system that eliminates the need for an external on-body transmitter. The system is designed for direct mobile device communication using embedded Bluetooth technology and aims for a one-year sensor life. Senseonics plans a pivotal study in 2027 and a potential commercial launch in 2028, building on the technology of its existing Eversense 365 product.
Analysts from Stifel Nicolaus and Bank of America Securities have provided insights on Senseonics Holdings (SENS) and Argenx Se (ARGX), both healthcare companies. Senseonics Holdings received a "Hold" rating from Stifel Nicolaus with a $9.00 price target, and a "Moderate Buy" consensus from analysts with a $13.00 price target. Argenx Se was maintained as a "Buy" by Bank of America Securities and Stifel Nicolaus, with a "Strong Buy" analyst consensus and a target price of $1182.58.
Barclays has initiated coverage on Senseonics Holdings (SENS) with an Equal-Weight rating and a $10.00 price target, recognizing potential growth but suggesting it may not outperform peers. Senseonics, a medical device company, is considered 18.6% undervalued according to GuruFocus's GF Value™ despite current unprofitability and a high P/S ratio. While the company exhibits strong growth and momentum with a GF Score™ of 72/100, concerns remain regarding its financial strength and profitability.
Senseonics Holdings, Inc. Director Steven Edelman received 1,292 shares of common stock as a quarterly retainer fee on October 1, 2026. These shares, valued at $12,868.32 based on a closing price of $9.96 per share, were issued instead of a cash payment. Following this transaction, Edelman's direct beneficial ownership in Senseonics totals 92,375 shares.
Senseonics Holdings, Inc. Director Douglas S. Prince received 815 common stock shares on October 1, 2026, as payment for quarterly retainer fees. These shares, valued at $9.96 each, were awarded under the company's non-employee director compensation plan. Following this transaction, Prince directly owns 70,146 shares of the company.